Drug intelligence / Profile preview

amoxicillin + clavulanic acid + methylprednisolone

Development stage
Phase 4
Lead developer
GSK
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

This is a combination drug consisting of three active ingredients:

  • Amoxicillin is a penicillin-type antibiotic that works by inhibiting bacterial cell wall synthesis, leading to the death of susceptible bacteria.
  • Clavulanic acid is a beta-lactamase inhibitor that prevents certain bacteria from breaking down amoxicillin, thereby extending its antibacterial spectrum.
  • Methylprednisolone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It acts by modulating gene expression to suppress inflammation and immune responses.

This combination may be used in clinical scenarios where both infection (requiring broad-spectrum antibiotic coverage) and significant inflammation (requiring corticosteroid therapy) are present. While combinations of antibiotics with steroids are sometimes used for conditions such as acute sinusitis or exacerbations of chronic obstructive pulmonary disease (COPD), there is limited evidence for the routine use of all three agents together in a single formulation. Each component has distinct mechanisms and indications.

02

Targets

Beyond the preview

Go deeper on amoxicillin + clavulanic acid + methylprednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + clavulanic acid + methylprednisolone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call